𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Early experience with a hybrid accelerated radiotherapy schedule for locally advanced head and neck cancer

✍ Scribed by Sandra Nuyts; Piet Dirix; Robert Hermans; Vincent Vander Poorten; Pierre Delaere; Caroline Weltens; Walter Van den Bogaert

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
326 KB
Volume
29
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background.

Our aim was to determine feasibility and efficacy of a hybrid radiotherapy schedule in locally advanced head and neck cancer.

Methods.

Seventy‐three patients with locally advanced head and neck cancer were irradiated according to a hybrid accelerated schedule consisting of 20 fractions of 2 Gy (once daily), followed by 20 fractions of 1.6 Gy (twice daily), to a total dose of 72 Gy.

Results.

Locoregional control was 55% after 2 years. Overall survival was 59%, disease‐specific survival was 63%, and disease‐free survival was 46%. Acute toxicity was prospectively scored in all 73 patients: the most frequent toxicities were mucositis (50.7%, grade 3), dysphagia (47.9%, grade 3), and dermatitis (34.5%, grade 3). All patients were treated to full dose, without treatment interruption.

Conclusion.

With this regimen, acceptable locoregional control and survival rates are achieved. Toxicity was well manageable, suggesting that a combination of this schedule with concomitant chemotherapy is possible and could lead to further improvement in the treatment of locally advanced head and neck cancer. © 2007 Wiley Periodicals, Inc. Head Neck, 2007

📜 SIMILAR VOLUMES

Hyperfractionated accelerated radiothera
Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer
✍ Gabriele K. Beckmann; Florian Hoppe; Leo Pfreundner; Michael P. Flentje 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB 👁 2 views

## Background: The purpose of this study was to determine the feasibility and efficacy of hyperfractionated accelerated radiotherapy (hfrcb) combined with simultaneous chemotherapy with weekly cisplatin (cddp) in locally advanced inoperable head and neck cancer. ## Methods: From august 1999 to de

Accelerated fractionation radiotherapy a
Accelerated fractionation radiotherapy and late intensification with 2 intra-arterial cisplatin infusions for locally advanced head and neck squamous cell carcinoma
✍ Kwok Hung Yu; Simon C. H. Yu; Edwin P. Hui; Michael K. M. Kam; Alexander C. Vlan 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract ## Background This study was established to determine the maximum tolerated dose of intra‐arterial cisplatin (IAC) concurrent with accelerated fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma (HNSCC). ## Methods We conducted a phase I study. Treat

Taxane-based chemoirradiation for organ
Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: Results of a phase II multi-institutional trial
✍ Anthony J. Cmelak; Barbara A. Murphy; Brian Burkey; Stacy Douglas; Yu Shyr; Jame 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 1 views

## Abstract ## Background. The optimal drug schedule and sequencing of chemotherapy and radiation for organ preservation in head and neck cancer has yet to be determined. We undertook a phase II trial of a taxane‐based induction chemotherapy (ICT) followed by a taxane‐based concurrent chemoradiati

Impact of nutrition support on treatment
Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: A secondary analysis of RTOG trial 90-03
✍ Rachel Rabinovitch; Barbara Grant; Brian A. Berkey; David Raben; Kie Kian Ang; K 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

## Background: The aim was to evaluate the relationship between nutrition support (ns) on host toxicity and cancer outcome in patients with locally advanced head and neck squamous cell carcinoma (hnscc) undergoing definitive radiotherapy (xrt). ## Methods: We performed a secondary analysis of rad

Docetaxel, cisplatin, and 5-fluorouracil
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck : The Dana Farber Cancer Institute experience
✍ Robert Haddad; A. Dimitrios Colevas; Roy Tishler; Paul Busse; Laura Goguen; Chri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Abstract ## BACKGROUND The authors conducted a series of four Phase I–II trials of high‐dose and intermediate‐dose docetaxel, cisplatin, and 5‐fluorouracil (TPF)‐based induction chemotherapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN). The chemotherapy regime

Concurrent chemoradiotherapy with weekly
Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53)
✍ Prakash B. Chougule; Muhammad S. Akhtar; Ritesh Rathore; James Koness; Robert Mc 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## Background. A phase II study was conducted using concurrent paclitaxel, carboplatin, and external beam radiotherapy (RT) in patients with advanced head and neck cancer. ## Methods. Forty‐three patients (stage III, __n__ = 12; stage IV, __n__ = 31) were treated with 8 cycles of wee